 The Menarini Group and Radius Health Incs NASDAQ: RDUS data from the phase 3 EMERALD trial evaluating elacestrant for ERHER2- advanced or metastatic breast cancer were published in the Journal of Clinical Oncology. The company says that elacestrant is the first oral. 